

RealRate

PHARMACEUTICAL 2018

Calithera Biosciences Inc. Rank 67 of 342





CALITHERA



PHARMACEUTICAL 2018



CALITHERA

RealRate

Calithera Biosciences Inc. Rank 67 of 342

The relative strengths and weaknesses of Calithera Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Calithera Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Calithera Biosciences Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 197%, being 151% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	167,667
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	39,027
Liabilities, Non-Current	0
Other Assets	23,029
Other Compr. Net Income	-257
Other Expenses	0
Other Liabilities	3,121
Other Net Income	1,860
Other Revenues	25,955
Property and Equipment	1,759
Research and Development	43,111
Selling, General and Administrative Expense	12,530

Output Variable	Value in 1000 USD
Assets	192,455
Liabilities	42,148
Expenses	55,641
Revenues	25,955
Stockholders Equity	150,307
Net Income	-27,826
Comprehensive Net Income	-27,954
Economic Capital Ratio	197%

